[HTML][HTML] Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
MM Awad, R Govindan, KN Balogh, DR Spigel… - Cancer Cell, 2022 - cell.com
Neoantigens arising from mutations in tumor DNA provide targets for immune-based
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
[HTML][HTML] Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
MM Awad, R Govindan, KN Balogh, DR Spigel… - Cancer Cell, 2022 - Elsevier
Neoantigens arising from mutations in tumor DNA provide targets for immune-based
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
MM Awad, R Govindan, KN Balogh, DR Spigel… - Cancer Cell, 2022 - profiles.wustl.edu
Neoantigens arising from mutations in tumor DNA provide targets for immune-based
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
MM Awad, R Govindan, KN Balogh… - Cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Neoantigens arising from mutations in tumor DNA provide targets for immune-based
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
[HTML][HTML] Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
MM Awad, R Govindan, KN Balogh, DR Spigel… - Cancer Cell, 2022 - cell.com
Neoantigens arising from mutations in tumor DNA provide targets for immune-based
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
MM Awad, R Govindan, KN Balogh, DR Spigel… - Cancer Cell, 2022 - europepmc.org
Neoantigens arising from mutations in tumor DNA provide targets for immune-based
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …
therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a …